The aim of this study was to assess the safety, tolerability, and antitumor activity of pembrolizumab in patients with PD-L1–positive, advanced thyroid cancer who were enrolled in the phase Ib KEYNOTE-028 trial. This evidence concerns the gene CD274 and thyroid cancer.